A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis

International Journal of Dermatology

Volumn 49, Issue 12, 2010, Pages 1368-1375

  Poulin, Yves ^a,b   Papp, Kim A ^c,d   Wasel, Norman R ^e,f   Andrew, Robin ^g   Fraquelli, Elisa ^g   Bernstein, Geula ^h   Chan, Daphne ^g  

^a LAVAL UNIVERSITY   (Canada)

^b Centre Dermatologique du Québec Métropolitain   (Canada)

^c K Papp Clinical Research   (Canada)

^d PROBITY MEDICAL RESEARCH   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f Stratica Medical Canada   (Canada)

^g Janssen Ortho Inc   (Canada)

^h Axon Medical Communications Group   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; NON PRESCRIPTION DRUG; PRESCRIPTION DRUG;

ADULT; ARTICLE; BODY SURFACE; CANADA; CONSUMER; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONLINE ANALYSIS; PATIENT SATISFACTION; PHOTOTHERAPY; PRESCRIPTION; PSORIASIS VULGARIS; SELF REPORT; UNSPECIFIED SIDE EFFECT;

CANADA; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHOTOTHERAPY; PSORIASIS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 78649405178     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04660.x     Document Type: Article

References (52)

1. Nall L, Gulliver W, Charmley P, Farber EM. Search for the psoriasis susceptibility gene: the Newfoundland Study. Cutis 1999; 64: 323-329.
2. Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M. Adalimumab, Alefacept, Efalizumab, Etanercept, and Infliximab for Severe Psoriasis Vulgaris in Adults: Budget Impact Analysis and Review of Comparative Clinical- and Cost-Effectiveness. [Technology Report No. 97.] Ottawa, ON: Canadian Agency for Drugs and Technologies in Health, 2007.
3. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15: 16-17.
4. De Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140-147.
5. Langley RG, Krueger CG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64: 18-23. discussion 4-5.
6. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008; 19: 5-21.
7. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64: 14-17.
8. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499.
9. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159: 2-9.
10. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007; 370: 272-284.
11. Guenther L, Langley RG, Shear NH, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg 2004; 8: 321-337.
12. Langley RG, Ho V, Lynde C, et al. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. J Cutan Med Surg 2006; 9: 18-25.
13. Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol 2008; 26: 438-447.
14. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-392.
15. Health Canada. Drugs and health products. Notice of compliance information. Alefacept. [Accessed January 13, 2009.]
16. Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm 2004; 10: 318-325.
17. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-1675.
18. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-1204.
19. Van De Kerkhof PC. How to position antipsoriatic treatments? J Dermatolog Treat 2006; 17: 325-326.
20. Pariser DM, Bagel J, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007; 143: 239-242.
21. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-285.
22. Van De Kerkhof PC, Kragballe K, Austad J, et al. Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicenter survey of psoriasis severity. Eur J Dermatol 2006; 16: 167-171.
23. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
24. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-139.
25. Nijsten J, Margolis DJ, Feldman SR, et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 2005; 52: 434-444.
26. Klotz J, Muir L, Cameron C, Delaney L. Monitoring a remote phototherapy unit via telemedicine. J Cutan Med Surg 2005; 9: 47-53.
27. Simpson GL, Yelverton CB, Rittenberg S, Feldman SR. Do utilization management controls for phototherapy increase the prescription of biologics? J Dermatolog Treat 2006; 17: 359-361.
28. Wasel N, Poulin Y, Andrew R, et al. A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. J Cutan Med Surg 2009; 13: 294-302.
29. Lynde CW, Poulin Y, Guenther L, Jackson C. The burden of psoriasis in Canada: insights from the psoriasis Knowledge IN Canada (SKIN) survey. J Cutan Med Surg 2009; 13: 235-252.
30. Mahler R, Jackson C, Ijacu H. The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey. J Cutan Med Surg 2009; 13: 283-293.
31. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol 2008; 26: 448-459.
32. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
33. Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis, June 2009. [Accessed February 14, 2010.]
34. Garcia-Diez A, Foraster CF, Sebastian FV, et al. What characterizes the severity of psoriasis? Results from an epidemiological study of over 3300 patients in the Iberian region. Dermatology 2008; 216: 137-151.
35. Patel V, Horn EJ, Lobosco SJ, et al. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. J Am Acad Dermatol 2008; 58: 964-969.
36. Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African-Americans: results from a population-based study. J Am Acad Dermatol 2005; 52: 23-26.
37. Van De Kerkhof PC. Psoriasis more than skin deep. J Dermatolog Treat 2008; 19: 4.
38. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
39. Skarpathiotakis M, Fairlie C, Ryan S. Specialized education for patients with psoriasis: a patient survey on its value and effectiveness. Dermatol Nurs 2006; 18: 358-361.
40. Van De Kerkhof PC, De Hoop D, De Korte J, et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000; 200: 292-298.
41. Papp K, Valenzuela F, Poulin Y, et al. Epidemiology of moderate to severe plaque psoriasis in a Canadian surveyed population. J Cutan Med Surg 2010; 14: 167-174.
42. Statistics Canada. Portrait of the Canadian population in 2006, by age and sex: national portrait. [Accessed January 1, 2010.]
43. Statistics Canada. Income of Canadians. [Accessed January 1, 2010.]
44. Farber EM, Nall ML. The natural history of psoriasis in 5600 patients. Dermatologica 1974; 148: 1-18.
45. Statistics Canada. Labour force characteristics, 2007. [Accessed January 2, 2010.]
46. Statistics Canada. Education indicators in Canada: an international perspective (2007 data). The Daily. September 8, 2009. [Accessed January 2, 2010.]
47. Martin LM, Leff M, Calonge N, et al. Validation of self-reported chronic conditions and health services in a managed care population. Am J Prev Med 2000; 18: 215-218.
48. Christensen TE, Callis KP, Papenfuss J, et al. Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J Invest Dermatol 2006; 126: 2397-2403.
49. Schmitt J, Ford DE. Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life, and depressive symptoms in patients with psoriasis - a structural equations modeling approach. Gen Hosp Psychiatry 2007; 29: 134-140.
50. Statistics Canada. Women in Canada. 5th edn, A Gender-Based Statistical Report. Ottawa, ON: Statistics Canada, 2006.
51. Statistics Canada. The Internet Experience of Younger and Older Canadians. Innovation Analysis Bulletin. Ottawa, ON: Statistics Canada, 2006.
52. Statistics Canada. Internet Use Rates, by Location of Access and Household Income. Ottawa, ON: Statistics Canada, 2003. [Accessed July 15, 2008.]